Moreover, apelin levels in insulin-resistant disorders, namely obesity, and T2DM, are increased, and apelin treatment increases insulin sensitivity, glucose tolerance, and fatty acid oxidation (114, 115), representing the effectiveness of exogenous apelin on diabetes-related complications. This evidence concerns the gene APLN and obesity due to melanocortin 4 receptor deficiency.